Study shows that nanoparticles release an anti-cancer microRNA inside lung cancer cells when stimulated using an alternating magnetic field.
Researchers are pursuing ever-more sophisticated treatments to tackle lung cancer. Traditional chemotherapy can have serious side-effects throughout the body, so many new treatments are highly targeted. These methods allow controlled release directly at the tumor using selective agents that are less likely to produce off-target effects.
An article published in Biomedical Engineering Advances presents such a strategy.
Nanosynth Group plc (LON:NNN) is focused on the synthesis and application of nanoparticles. The group uses a patented process developed by Dr Cave at Nottingham Trent University. It has three subsidiaries; Pharm 2 Farm Ltd, nanosynth ltd and Cloudveil.